Table 2.
Base Case Results
| Strategy | QALYs Per Person | Cost Per Person | Discounted Incremental Cost Per QALY Gained | Discounted Incremental Cost Per QALY Gained* |
|---|---|---|---|---|
| Referent strategy | 21.0649 | $11,242 | — | — |
| Clinical criteria and algorithm strategies | ||||
| Amsterdam/IHC | 21.0949 | $12,933 | — | — |
| Amsterdam/germline | 21.1010 | $13,282 | — | — |
| MMRpredict/IHC | 21.1448 | $15,319 | — | — |
| MMRpredict/germline | 21.1612 | $16,375 | — | — |
| MMRpro/IHC | 21.1680 | $16,455 | $50,562 | |
| PREMM/IHC | 21.1692 | $16,920 | — | |
| Bethesda/IHC | 21.1767 | $17,021 | $65,347 | |
| MMRpro/germline | 21.1891 | $17,873 | $68,384 | |
| PREMM/germline | 21.1905 | $18,829 | — | |
| Bethesda/germline | 21.1995 | $18,737 | $82,864 | — |
| Tumor-testing strategies | ||||
| IHC | 21.2012 | $19,381 | — | — |
| IHC/BRAF | 21.2012 | $19,551 | — | $59,719 |
| MSI | 21.2045 | $21,155 | — | — |
| MSI plus IHC | 21.2249 | $23,833 | — | $179,576 |
| MSI plus IHC/BRAF | 21.2249 | $23,642 | $193,343 | — |
| Upfront germline testing | 21.2500 | $33,492 | $393,303 | $271,219 |
Abbreviations: IHC, immunohistochemistry; MSI, microsatellite instability testing; QALY, quality-adjusted life-year.
*
Excluding clinical criteria strategies.